Boston Scientific Profit, Sales Rise but Issues Soft Guidance
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.7 per share a year ago.
Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply.
The medical-device maker beats quarterly earnings expectations but offers a disappointing outlook for the current quarter.
Boston Scientific (BSX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top-and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings?
BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Boston Scientific (BSX) stood at $92.51, denoting a +1.34% move from the preceding trading day.
Down 6.3% in 4 Weeks, Here's Why Boston Scientific (BSX) Looks Ripe for a Turnaround
Boston Scientific (BSX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
How Low Can Boston Scientific Stock Go When Markets Turn Sour?
Boston Scientific (BSX) shares have decreased by 8.5% over the past 5 trading days. This recent drop highlights revived worries regarding the initial earnings dilution stemming from its Penumbra acquisition, yet such significant declines often raise a challenging question: is this weakness transitory, or does it indicate more profound issues within the company?
Boston Scientific Corporation (BSX) M&A Call Transcript
Boston Scientific Corporation (BSX) M&A Call Transcript
BSX Stock May Gain From Newly Inked Deal to Buy Valencia Technologies
Boston Scientific stock may rebound after agreeing to buy Valencia Technologies, adding the FDA-approved eCoin ITNS device to expand its Urology portfolio.
Boston Scientific Corporation (BSX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Boston Scientific Corporation (BSX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Boston Scientific (BSX) reached $95.72 at the closing of the latest trading day, reflecting a -1.97% change compared to its last close.
